Hi-Risk/Recurrent/Advanced PCa Video Chat, March 31, 2025

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostic.

If you missed any recent recordings, you’ll find a full list either on our YouTube Playlist or visit our Blog Post https://ancan.org/our-recent-blog-posts-in-case-you-missed-them/ Sign up for our Blog by checking the New Blog box at https://ancan.org/contact-us/

AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.

AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.

AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download

All AnCan’s groups are free and drop-in … join us in person sometime!

You can find out more about our 11 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/
Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/

Join our other free and drop in groups:

Under 60 Stage 3&4 Prostate Cancer – 2nd Thursdays @ 7pm Eastern in AnCan Barniskis Room
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 4th Thursday @ 8.00 pm Eastern https://ancan.org/veterans

Complete Richard Wassersug’s E2/estradiol survey – open to all https://qualtricsxmxjhxcwlhx.qualtrics.com/jfe/form/SV_2h2GxUXB1lWMT9I

Editor’s Pick: Mutations that favor and hinder Pluvicto success (rd)

Topics Discussed

CDMRP Prostate Cancer Research Program; new Pluvicto FDA approval; after 12 years, 78 yr old reaches 4+4 and must consider treatment; more around staying on bone strengtheners; could E2 be a twofer for bones and ADT?; which mutations enhance and which hinder Pluvicto; AUS complicates other surgical procedures; E2/estradiol survey to be presented at AUA25; RT proctitis; switching to Yale Smilow;

Chat Log

John A

sent: 5:16 PM

If you are currently a reviewer, please send me a chat message. thanks, John dr.john@ancan.org
Doug D Portland, OR

sent: 5:17 PM

Doug DuFresne participated
Gary V Portland, Oregon

sent: 5:18 PM

Cut for 2025 was 57% of 2024 budget ..from $1.509 billion to $650 million
Gary V Portland, Oregon

sent: 5:23 PM

That info came from “Perplexity” I did not do the math…
AnCan – rick

sent: 5:27 PM

rd@ancan.org
AnCan – rick

sent: 6:00 PM

Axumin
AnCan – rick

sent: 6:07 PM

https://clinicaltrials.gov/ct2/show/NCT03745716
AnCan – rick

sent: 6:07 PM

https://www.aprea.com/clinical-trials/
Len Sierra

sent: 6:30 PM

APR-246, also known as eprenetapopt, is a small molecule that reactivates mutant p53, a tumor suppressor protein, and has shown promise in treating TP53-mutated cancers, particularly in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Len Sierra

sent: 6:31 PM

From ASCO GU 2024: TITLE: Association of prior PARP inhibitor therapy with response to 177Lu-PSMA-617 (LuPSMA) in men with DNA damage repair (DDR) mutations.
Len Sierra

sent: 6:32 PM

Conclusions: Prior receipt of PARPi therapy appears to negatively associate with the clinical activity of LuPSMA. These data support the hypothesis that PARPi therapy may lead to clinically significant cross-resistance with LuPSMA

Hi-Risk/Recurrent/Advanced PCa Video Chat, March 31, 2025